Major players in the contract development and manufacturing organization industry gathered in New York City this week to provide updates on their infrastructure investments.
Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.
It’s been a topsy-turvy week for President Trump’s tariff proclamations, which have created anxiety and confusion for businesses that rely on trade with Canada and Mexico.
The Indiana-headquartered pharma giant chose to make its investment announcement this week in Washington, D.C., with newly confirmed Commerce Secretary Howard Lutnick.
In 2025, Charles River’s contract development and manufacturing organization business is set to struggle, while Siegfried’s growth outlook is fueled by strong demand.
India’s Global Calcium and China’s Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical are the latest to be hit with warning letters from U.S. regulators.
President Trump has for now suspended a 25% levy on imports from Canada, but the looming tariff threat was a hot topic of discussion at a life sciences summit in Toronto.
Switzerland-based Lonza, the world’s largest CDMO by revenue, reported mixed full-year results this week but CEO Wolfgang Wienand promised significant growth potential ahead.
Just days apart, the company was hit with a Complete Response Letter and a clinical hold related to the FDA’s inspection findings at a third-party manufacturing facility.
This week, CEOs from Charles River, Thermo Fisher, and WuXi Biologics provided mixed outlooks for 2025 at the J.P. Morgan Healthcare Conference in San Francisco.
The companies used Sutro Biopharma’s proprietary cell-free expression technology on a commercial scale to manufacture Sutro’s luvelta, an antibody-drug conjugate.
With China aggressively pursuing a strategy to become the world’s leader in biotech, America must invest in biomanufacturing to maintain its global dominance.
The week’s biggest announcement was WuXi AppTec’s sale of WuXi Advanced Therapies, its cell and gene therapy unit, to U.S.-based private equity firm Altaris.
The acquisition, which took the global contract development and manufacturing organization private, is a one-off the likes of which the industry will not see again.
The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.
